The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.
M. C. U. Cheang
No relevant relationships to disclose
D. Voduc
No relevant relationships to disclose
D. Tu
No relevant relationships to disclose
S. Jiang
No relevant relationships to disclose
S. Leung
No relevant relationships to disclose
S. K. L. Chia
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
M. N. Levine
No relevant relationships to disclose
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience; AstraZeneca; Boehringer Ingelheim; Pfizer; Roche
Honoraria - Abraxis BioScience; AstraZeneca; Boehringer Ingelheim; Pfizer; Roche
Expert Testimony - AstraZeneca (U); Novartis (U)
T. Vickery
No relevant relationships to disclose
S. Davies
No relevant relationships to disclose
I. J. Stijleman
No relevant relationships to disclose
C. Davis
No relevant relationships to disclose
J. S. Parker
No relevant relationships to disclose
M. J. Ellis
Employment or Leadership Position - University Genomics (U)
Stock Ownership - Bioclassifier
P. S. Bernard
Employment or Leadership Position - University Genomics (U)
Consultant or Advisory Role - University Genomics (U)
Stock Ownership - Bioclassifier
C. M. Perou
Employment or Leadership Position - University Genomics (U)
Stock Ownership - Bioclassifier
T. O. Nielsen
Stock Ownership - Bioclassifier